{
  "source": "PA-Notification-Austedo.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1236-10\nProgram Prior Authorization/Notification\nMedication Austedo® (deutetrabenazine), Austedo® XR (deutetrabenazine)\nP&T Approval Date 11/2017, 11/2018, 11/2019, 11/2020, 2/2022, 2/2023, 4/2023, 4/2024,\n4/2025\nEffective Date 7/1/2025\n1. Background:\nAustedo and Austedo XR are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated\nin adults for the treatment of chorea associated with Huntington’s disease and for the treatment\nof tardive dyskinesia.\n2. Coverage Criteriaa:\nA. Tardive Dyskinesia\n1. Initial Authorization\na. Austedo or Austedo XR will be approved based on the following criterion:\n(1) Diagnosis of tardive dyskinesia\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months.\nB. Chorea associated with Huntington’s disease\n1. Initial Authorization\na. Austedo or Austedo XR will be approved based on the following criterion:\n(1) Diagnosis of chorea associated with Huntington's disease\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services Inc.\n1\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits, Step Therapy, and/or Medical Necessity may be in place\n4. References:\n1. Austedo – Austedo XR [package insert]. Parsippany, NJ: Teva Pharmaceuticals Inc.;\nFebru",
    "/or therapeutic class.\n• Supply limits, Step Therapy, and/or Medical Necessity may be in place\n4. References:\n1. Austedo – Austedo XR [package insert]. Parsippany, NJ: Teva Pharmaceuticals Inc.;\nFebruary 2025.\nProgram Prior Authorization/Notification - Austedo (deutetrabenazine), Austedo\nXR (deutetrabenazine)\nChange Control\n11/2017 New program\n2/2018 Administrative change to correct effective date.\n11/2018 Annual review. No changes to clinical coverage criteria.\n11/2019 Annual review. No changes to clinical coverage criteria. Updated\nreference.\n11/2020 Annual review. Updated reference.\n2/2022 Annual review with no change to clinical criteria. Reference updated.\n2/2023 Annual review. Updated background per package insert and updated\nreference.\n4/2023 Added coverage criteria for Austedo XR formulation per prescribing\ninformation. Updated background and references.\n4/2024 Annual review with no change to clinical criteria. Reference updated.\n4/2025 Annual review with no change to clinical criteria. Reference updated.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}